Stem Cell Therapy for Retinitis Pigmentosa

What This Article Covers

Retinitis pigmentosa (RP) is a group of inherited retinal diseases that slowly destroy the light-sensing photoreceptor cells in the eye, and it has become one of the more active proving grounds for cell-based therapy in ophthalmology. This article summarizes what actual human trials — from injected retinal progenitor cells to a patient's own bone marrow stem cells to lab-grown photoreceptors — have shown so far, and what remains unproven.

Overview

Retinitis pigmentosa is a genetic condition, usually caused by mutations in one of dozens of possible genes, that causes rod and cone photoreceptors in the retina to degenerate over years to decades. It typically begins with night blindness and a shrinking visual field, and can progress to severe central vision loss. There is no cure, and current medical options are limited — the main FDA-approved treatment is a gene therapy (Luxturna) available only to the small subset of patients with a specific RPE65 gene mutation. Because RP affects a huge range of underlying genes, cell-based approaches that aim to protect or replace retinal tissue rather than fix one gene at a time have drawn significant research interest.

How It's Thought to Work

Researchers are pursuing a few distinct strategies. One uses human retinal progenitor cells (immature cells destined to become retina) injected into the vitreous, with the hypothesis that they release protective growth factors that rescue struggling photoreceptors rather than physically replacing them. Another uses a patient's own bone-marrow-derived stem cells, injected near the retina, in the hope that they support the blood supply and secrete factors that slow degeneration. A newer approach uses induced pluripotent stem cells (iPSCs) — adult cells reprogrammed into a stem-cell-like state and then coaxed into becoming actual photoreceptors or retinal pigment epithelium — with the goal of physically replacing lost retinal tissue. None of these are approved therapies; all remain investigational.

What the Evidence Shows

The most advanced data comes from jCyte's jCell program, using human retinal progenitor cells. In a randomized, sham-controlled Phase 2b trial of 84 RP patients, the group receiving a higher dose (6 million cells) showed a mean gain of 7.43 letters of visual acuity at 12 months versus 2.81 letters in the sham group — and in a post-hoc analysis of patients with reliable fixation and similar vision in both eyes, the high-dose group gained 16.27 letters versus 1.85 for sham, a difference reported as statistically significant (p=0.003), per jCyte's announced results and CIRM's trial summary. Secondary measures — contrast sensitivity, visual field, and low-light mobility — also trended in favor of the higher dose. Safety was reassuring at the high dose, though one Grade 3 ocular hypertension event occurred in the lower-dose group. This is a genuinely encouraging signal, but it is a single company-reported Phase 2b result, the primary post-hoc finding was drawn from a subgroup, and it has not yet been replicated in a completed pivotal trial.

A separate, smaller Phase 1 trial at UC Davis tested a different approach entirely: injecting patients' own CD34+ bone marrow stem cells. Among 7 participants with advanced RP and substantial peripheral vision loss, the treatment was well tolerated with only one minor, self-resolving complication, and four of the seven patients (57%) showed measurable improvement on objective vision tests, with most reporting subjective gains, according to a November 2024 report in Ophthalmology Science and UC Davis Health's coverage. This is a small, uncontrolled, hypothesis-generating study — real and worth watching, but nowhere near proof of benefit.

Looking further out, BlueRock Therapeutics (a Bayer subsidiary) received FDA clearance in September 2024 to begin a Phase 1/2a trial of iPSC-derived photoreceptor cells (OpCT-001) for advanced RP, with enrollment expected in 2025; this trial is designed to test safety first and has not yet reported human efficacy data. A broader 2025 review of stem cell therapy in ophthalmology (PMC) describes the field as early-stage, with safety established in small cohorts but durable efficacy still unproven.

Who Might Be a Candidate

• Adults with a confirmed genetic diagnosis of retinitis pigmentosa, ideally through a retina specialist or genetic counselor
• Patients with moderate to advanced vision loss (e.g., visual acuity roughly in the 20/80 to 20/800 range in past trials) who still have some retained retinal structure
• Those who do not carry the specific RPE65 mutation eligible for the approved gene therapy Luxturna, or who have exhausted other options
• People willing to enroll in a registered clinical trial (searchable at ClinicalTrials.gov) rather than pay for an unproven clinic-based “stem cell” injection
• Patients who understand the therapy is experimental, with unresolved questions about durability, dosing, and which patients respond best
• Individuals in reasonably good general health who can tolerate an intravitreal or periocular injection procedure and multi-year follow-up visits

Bottom Line

Stem cell approaches for retinitis pigmentosa are among the more promising areas in regenerative ophthalmology, with one Phase 2b trial reporting a statistically significant vision gain in a treated subgroup and multiple other trials showing an encouraging safety profile. But no stem cell therapy for RP is FDA-approved, results so far come from small or subgroup analyses that need confirmation in larger controlled trials, and effect sizes and durability remain uncertain. Patients interested in these therapies should pursue enrollment in legitimate, registered clinical trials — and be wary of any clinic offering “stem cell” injections for RP outside of a trial setting, since these are not proven or approved treatments.